Home > Oncology > ASCO GU 2022 > Urothelial Carcinoma > Maintenance niraparib fails to improve PFS in advanced urothelial cancer

Maintenance niraparib fails to improve PFS in advanced urothelial cancer

Presented By
Dr Francesca Vignani, Ordine Mauriziano Hospital, Italy
Conference
ASCO GU 2022
Trial
Phase 2, Meet-URO12
The Meet-URO12 trial of maintenance niraparib in advanced urothelial cancer patients without progression after first-line chemotherapy failed to meet its primary endpoint of improvement in progression-free survival (PFS). Homologous recombination deficiency (HRD) is present in 10–25% of advanced urothelial carcinomas and sensitises cancer cells to both platinum-based chemotherapy and PARP inhibitors [1,2]. This offers a rationale for maintenance therapy with a PARP inhibitor in patients with advanced urothelial carcinoma who obtained an objective response or stable disease with first-line platinum-based chemotherapy. Meet-URO12 (NCT03945084) is a phase 2, prospective, randomised, open-label, multicentre study conducted in patients with locally advanced or metastatic urothelial carcinoma who show no evidence of progression after 4–6 cycles of first-line plati...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on